On the stock market since 2014, it operates in the world of health and science. It has 17,000 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 9% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 55% below its peak. The market has trimmed its expectations for the company.
The company sells $4.4B a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $74.25 — 17% above today’s price.
A loss of $1.0B against $4.4B in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CTLT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CTLT has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.